摘要
目的探讨奥曲肽治疗肝硬化食管胃底静脉曲张破裂出血的临床与对止血时间的影响。方法将86例肝硬化EGVB患者随机分为观察组和对照组,每组各43例。在常规治疗的基础上,观察组予以奥曲肽与奥美拉唑治疗,对照组予以酚妥拉明与奥美拉唑治疗。观察两组患者的临床疗效、效率和安全性指标。结果治疗结束后,两组患者的出血均不同程度的得以控制。观察组的平均止血时间短于对照组,输血量少于对照组,再出血率低于对照组;观察组与对照组的总有效率分别为88.37%、69.77%,不良反应发生率分别为4.65%、20.93%,上述差异均具有统计学意义(P<0.05或P<0.01)。结论奥曲肽联合奥美拉唑治疗肝硬化EGVB具有疗效确切、作用迅速、使用方便、安全性高的特点,特别适用于基层医疗单位肝硬化EGVB患者的急救治疗。
OBJECTIVE To explore effect of Octreotide combined with Oneprazole for treating liver cirrhosis with esophagogastr-varicosis and fissure bleeding （EGVB） and its influence on hemostasis time. METHODS 86 eases of liver cirrhosis patients with EGVB were randomly divided into observation group and control group, 43 cases in each group.Based on the routine treatment, patients in observation group were given Octreotide and Omeprazole, and patients in control group were given Phentolamine and Omeprazole. Clinical effect, efficiency and safety index were observed in patients of two groups. RESULTS Bleeding of all patients in two groups were some controlled after treatment.Average bleeding time of observation group was shorter than that in control group, blood transfusion amount was less, and rebleeding rate was lower than that in control group. Total efficiency were 88.37 % and 69.77 %, and adverse reactions incidence were 4.65 % and 20.93 % in observation group and control group, and there were significant differences in all the above indicators （ P 〈 0.05 or P 〈 0.01）. CONCLUSION It has features of definite and rapid effect, convenient by octreotide and posterior pituitary hormone, so it is patients with EGVB in basic medical units. to use, and high safety of treating liver cirrhosis with EGVB especially suitable for emergency treatment to liver cirrhosis
出处
《海峡药学》
2013年第1期76-78,共3页
Strait Pharmaceutical Journal
关键词
肝硬化
食管胃底静脉曲张破裂出血
奥曲肽
奥美拉唑
Liver cirrhosis
Esophagogastr-varicosis and fissure bleeding（EGVB）
Octreotide
Omeprazole
